Brain-derived neurotrophic factor (BDNF) Val 66 Met genotype has been associated with neurobehavioral deficits. To examine its relevance for addiction, we examined BDNF genotype differences in drug-seeking behavior. Heroindependent volunteers (n = 128) completed an interview that assessed past-month naturalistic drug-seeking/use behaviors. In African Americans (n = 74), the Met allele was uncommon (carrier frequency 6.8%); thus, analyses focused on European Americans (n = 54), in whom the Met allele was common (carrier frequency 37.0%). In their natural setting, Met carriers (n = 20) reported more time-and cost-intensive heroin-seeking and more cigarette use than Val homozygotes (n = 34). BDNF Val 66 Met genotype predicted 18.4% of variance in 'weekly heroin investment' (purchasing time ¥ amount ¥ frequency). These data suggest that the BDNF Met allele may confer a 'preferred druginvested' phenotype, resistant to moderating effects of higher drug prices and non-drug reinforcement. These preliminary hypothesis-generating findings require replication, but are consistent with pre-clinical data that demonstrate neurotrophic influence in drug reinforcement. Whether this genotype is relevant to other abused substances besides opioids or nicotine, or treatment response, remains to be determined.
Genetic association studies of addictive disorders typically attempt to identify polymorphisms underlying initial vulnerability (e.g. Enoch et al. 2009; Saccone et al. 2009; Yuferov et al. 2010 ). Yet, genetic influences may operate at various stages of the addiction cycle (Li & Burmeister 2009; Khokhar et al. 2010) . Little is known about which biologically plausible functional genotypes alter persistence of addictive behaviors. Improved knowledge could help predict resistance to, or benefit from, treatments. Unlike studies of vulnerability, genetic studies of addictive persistence target individuals who are already drug-dependent because the goal is to understand genotypic and phenotypic heterogeneity within the clinical population.
Substance use disorders are complex syndromes that are not ideally suited for genetic studies (Wong & Schumann 2008) . Phenotype selection requires a targeted approach (Gottesman & Gould 2003; Ducci & Goldman 2008; Lerman, Perkins & Gould 2009 ). Assessing an intermediate phenotype (versus a broader phenotype such as a nosological condition) is preferable because a circumscribed measure will tend to be more reliable (which improves power to find associations with the genotype) and perhaps more closely related to genetic underpinnings than a multifactor syndrome. In the present research, we selected drug-seeking behavior (intermediate phenotype) by heroin-dependent, out-oftreatment volunteers because (1) individual drugseeking patterns are periodic (within days) and stable (between days) due to physical dependence and motivation to avoid opioid withdrawal signs/symptoms (Koob and Le Moal, 2001 ); and (2) this characteristic pattern enables investigation to focus on predictive validity, i.e. whether genetic heterogeneity within this group explains phenotypic variance. Our approach emphasizes the drug user's habitual purchasing costs (time and money), which capture behavioral investment in this drug-seeking repertoire. We control for enabling environmental factors (e.g. income, drug cost and supply), which are presumably orthogonal to genetic influence. Finally, because cigarette smoking is highly prevalent among heroin-dependent individuals, we examined whether genotypic effect is limited to opioid-seeking behavior or may also apply to nicotine-reinforced behavior (as cigarette smoking also follows a highly period and stable pattern), i.e. behavioral specificity.
Brain-derived neurotrophic factor (BDNF) is the most widely distributed neurotrophin and is involved in neurogenesis, differentiation, survival and synaptic plasticity (Lu 2003; Lipsky & Marini 2007; Russo et al. 2009 ). BDNF secretion is activity-dependent-e.g. increased by cognition and exercise, and decreased by stressors-and modulates neurotransmission in dopamine, glutamate, gamma-aminobutyric acid and serotonin systems (e.g. Goggi et al. 2002; Carvalho et al. 2008) . The human BDNF gene encodes a 247 amino acid pre-protein (pro-BDNF) that is cleaved to form an evolutionarily conserved 120 amino acid mature protein (Maisonpierre et al. 1991) . A single nucleotide polymorphism (SNP; rs6265) results in methionine substitution for valine at codon 66 (Val 66 Met). The evolutionarily recent, less-frequent Met allele alters the pro-BDNF protein sequence, which disrupts trafficking and results in less activity-dependent BDNF secretion without affecting the mature BDNF sequence Lu 2003; Chen et al. 2004) .
As might be expected from its neurotrophic physiological influence, the BDNF Val
66
Met genotype has unsurprisingly been associated with pleiotropic effects. Met allele carriers exhibit several reliable intermediate phenotypes: reduced gray matter volume in the hippocampus (Pezawas et al. 2004; Szeszko et al. 2005; Bueller et al. 2006; Frodl et al. 2007 [European/Caucasian] ) and dorsolateral prefrontal cortex (e.g. Hariri et al. 2003) , and impaired hippocampal-dependent memory function Hariri et al. 2003 [Caucasian] ). In the realm of substance use, the BDNF
Met allele has been associated with headache-related overuse of non-opioid analgesics (Di Lorenzo et al. 2008) , increased risk of nicotine dependence (Lang et al. 2007 [German] ) and earlier onset of alcohol dependence (Matsushita et al. 2004 [Japanese] ), but decreased risk of dependence on heroin (Cheng et al. 2005 [Han Chinese] ) and protection against post-treatment alcohol relapse (Wojnar et al. 2009 [Polish] Met genotype has neurobiological and clinical relevance, findings from animal studies further suggest that BDNF physiology influences opioid-dependence behaviors. Chronic opioid exposure alters BDNF/TrkB receptor-mediated dopamine function in the ventral tegmental area (VTA; Bolanos & Nestler 2004; Russo et al. 2009 ) and its projection to the nucleus accumbens, the key neural circuitry underlying opioid reinforcement. Experimental infusions of BDNF directly into the VTA produce drug-seeking (Lu et al. 2004 ) and biochemical changes (Berhow et al. 1995; Sklair-Tavron et al. 1996; Vargas-Perez et al. 2009 ). Discontinuation of chronic opioid exposure leads to increased BDNF mRNA expression in brain regions underlying physical dependence and drug-seeking (Numan et al. 1998; Hatami et al. 2007) . BDNF mRNA expression in prefrontal cortex is upregulated following exposure to psychostimulants and morphine, but to a lesser extent with nicotine (Le Foll, Diaz & Sokoloff 2005) .
Given that the BDNF
Met allele has been linked to impaired hippocampal and frontal-cortical morphology and learning/memory problems, and thus impaired behavioral flexibility, we theorized that the Met allele might confer resistance to environmentally or pharmacologically induced changes in drug-seeking/use. If true, then the Met allele could have opposite effects at different stages of addiction, i.e. protecting against initial vulnerability (thus explaining counterintuitive results by Cheng et al. 2005) while making it more difficult to modify chronic drug-seeking/use (i.e. harder to unlearn). Thus, we asked: Do heroin-dependent Met allele carriers exhibit greater drug-seeking behavior in the context of non-drug environmental alternatives? Our aim was to determine the extent of BDNF Val 66 Met associations with behavioral investment in opioid-seeking.
MATERIALS AND METHODS

Participants
This investigation encompasses three source studies approved by Investigational Review Boards at Wayne State University and the University of Michigan (for methodological details, see Greenwald & Hursh 2006; Greenwald & Steinmiller 2009; Greenwald 2010) , and conducted in accordance with the Declaration of Helsinki. Certificates of confidentiality were obtained from the National Institute on Drug Abuse. Male and female volunteers, 18-55 BDNF and drug-seeking behavior 837 years old, were recruited from the Detroit area using newspaper ads and word-of-mouth. Ethnicity and race were not exclusion factors, but, due to low frequency of other racial/ethnic groups, only African American (AA) and European American (EA) subjects were included in the present data analyses. Those identifying themselves as heroin-dependent and not seeking treatment were instructed to call for a telephone interview. The screening process included informed consent, providing demographic data, comprehensive substance use and medical histories, and an interview lasting 20-30 minutes that was used to obtain specific data about past-month income, drug purchasing and use factors (see below). All participants reported current daily heroin use, provided a urine sample that was positive for opioids (> 300 ng/ml), and were diagnosed with current opioid dependence based on clinician interview using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Urine samples were also tested for methadone, cocaine, benzodiazepines, cannabinoids and barbiturates. Volunteers had to provide an alcohol-free breath sample (< 0.002%). Participants were paid $30 for completing the first screening visit, and those who continued in screening toward qualifying for laboratory-based studies could earn $25 more over two subsequent screening visits.
Genotyping
The Golden Gate drug addiction Illumina panel (Hodgkinson et al. 2008 ) was used to genotype blood samples provided by each participant. Whole blood (6 ml/subject) was collected into ethylenediaminetetraacetic acid tubes and DNA was extracted using Oragene DNA self collection kit (Qiagen, Valencia, CA, USA) (formerly Gentra Puregene kit).
Due to the relatively rare BDNF rs6265 Met/Met genotype (see Table 1 ), all analyses contrasted Met carriers (Met/Met + Met/Val) with Val homozygotes. To examine the specificity of the BDNF rs6265 polymorphism, four BDNF variants with relatively high minor allele frequencies (> 0.25) located in the 3′ untranslated (UTR) region (rs1519480, rs7124442, rs7934165 and rs11030121) were also included in the analyses. All of these 3′ UTR SNPs were in linkage disequilibrium (LD) with the functional SNP (rs6265), and all were in LD with each other. Furthermore, none of the 3′ UTR SNPs was significantly related to the phenotypes tested here. For this reason, these 3′ UTR SNPs are not mentioned further.
Phenotyping measures
Phenotypes were derived from a semi-structured interview that was previously validated with heroin abusers (Roddy & Greenwald 2009; Roddy, Steinmiller & Greenwald 2011) . Participants were asked a series of interrelated questions to ascertain past-month sources and amounts of income (legal and illegal), heroin price, estimated purity, all drug and non-drug expenditures, drugacquisitive behaviors (e.g. purchase time, amount spent and purchasing frequency) and heroin consumption (e.g. bags per day, including the distribution of use throughout the day). To examine the behavioral specificity of BDNF genotype on drug-seeking, we also ascertained daily cigarette use, alcohol use and illegal drug use as part of a comprehensive substance use history questionnaire.
Data analyses
BDNF Val 66
Met genotype and allelic distributions were computed for each ancestral group (Table 1 ). Genotype frequencies were tested for Hardy-Weinberg equilibrium using a web-based calculator (http://scienceforall.org/ 2010/06/20/hardy-weinberg-equilibrium-calculator/). Analyses were conducted using SPSS v.19 (SPSS Inc., Chicago, IL, USA). BDNF genotype comparisons on categorical variables [other BDNF genotypes, race, gender, route of heroin use (injection versus non-injection), ever overdosed on heroin, and lifetime psychiatric diagnoses] were performed using c 2 tests. BDNF genotype comparisons for continuous variables were conducted using oneway analysis of variance (ANOVA; Table 2 ). Descriptive statistics are presented as means Ϯ 1 standard deviation (SD). For all analyses, the criterion for null hypothesis rejection was set at nominal P < 0.05.
Variables that were not normally distributed (see below) were log10-transformed for correlation and regression analyses. See Figure 1 for distributions of heroinpurchasing measures. We conducted tests of BDNF genotype effect for key measures of drug-seeking/use behavior, and for control variables that-while not hypothesized as related to the genotype-might need to be included as covariates in regression analyses; Table 2 lists these variables. Pearson's correlations were computed among behavioral economic measures (Fig. 2) , including drug supply factors (log10 past-month income, number of heroin suppliers and unit cost), heroinpurchasing pattern (log10 time, log10 amount and log10 frequency; percent of income spent on heroin), heroin consumption (log10 total daily bags used) and non-heroin expenses (percent of income spent on food, shelter/ utilities, and cigarettes). This was also done to identify control variables for regression analyses in which we predicted different heroin-seeking phenotypes (Table 3) . We derived a novel heroin-purchasing summary score, 'weekly heroin investment' [log10 purchase time ¥ purchase amount ¥ number of weekly purchases], expressed in dollar-minutes weekly. (14) 36 (24) a Effect sizes and power are for log10-transformed variables. See text. Psychiatric diagnostic data (based on SCID) were available for fewer participants than in the overall sample. Sample sizes are shown in parentheses adjacent to each percentage for each diagnosis. Substance use disorders refer to meeting criteria for lifetime abuse or dependence. Antisocial personality disorder refers to cases that also met criteria for childhood conduct disorder. Due to the smaller group sizes for DSM-IV diagnoses, statistical differences were not evaluated. DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; IQ = intelligence quotient
RESULTS
Participant characteristics
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EAs (n = 54) and overall sample (n = 128). Genotype frequencies for rs6265 did not deviate significantly from Hardy-Weinberg equilibrium in the European-or African-descent groups or the overall sample. Allele frequencies significantly differed between races, with the Met allele extremely rare in AA. Separate analyses were performed for EAs and AAs. For the present purposes, we primarily report results for EAs and include data for AAs in the supplementary materials.
BDNF Val 66
Met effect on drug-seeking/use
Univariate analyses
Some continuous measures of heroin-seeking and income were not normally distributed. Figure 1 shows the distributions of responding by BDNF rs6265 genotype (Met carriers versus Val homozygotes) for three primary heroin-seeking phenotypes: typical purchase time (minute), average purchase amount (dollars), number of weekly purchases and an empirically derived index referred to as 'weekly heroin investment' that is the product of these three measures (purchase time ¥ purchase amount ¥ weekly purchases). Figure S1 compares the distributions of these four phenotypes in EAs and AAs. Figure 2 illustrates the covariance among these phenotypes in EAs, while demonstrating Val 66 Met genotype differences in these response distributions.
BDNF
One-way ANOVAs found significant BDNF rs6265 genotype differences such that Met carriers had longer purchase times and higher unit purchase amounts than Val homozygotes (see Table 2 ). Similar non-significant tendencies (P's < .15) were observed for Met carriers to report longer duration of heroin use, more likely to inject heroin, and more daily bags consumed. Met carriers also reported marginally higher total past-month income. Table S1 provides comparable data for AA subjects.
Multivariate analyses
Multivariate ANOVA (MANOVA) was used to ascertain whether results remained significant for the four primary outcomes (purchase time, unit purchase amount, weekly purchases and daily bags consumed) when adjusting for multi-collinearity among these measures (Fig. 2) ; the 'heroin investment' measure was excluded because it was derived directly from the first three measures. The MANOVA confirmed that the BDNF genotype effect remained significant, Hotelling F(4,49) = 3.17, P = .022.
Stepwise multiple regression analyses were used to determine whether Val 66 Met genotype and control variables predicted measures of heroin-seeking in the natural Table 3 , regression analysis) 
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environment. Initial analyses were stratified by ancestral race (EA versus AA), after we determined this factor explained significant variance on some measures. In AAs, the infrequent Met allele was not related to any heroin-seeking measure but due to its rarity, there was little power in the AA sample to detect such an effect. Thus, final regression analyses focused on EAs. Covariates in all these analyses were age, number of heroin suppliers, current injection heroin use and total pastmonth income. Table 3 shows that, in EAs (n = 54), BDNF Met allele carriers (n = 20) had significantly longer heroinpurchasing times and higher purchase amounts than Val homozygotes (n = 34), which accounted for 11.1% and 7.6% of variance in these outcomes, respectively. BDNF Met carriers had significantly higher 'weekly heroin investment' scores than Val homozygotes (see Fig. 1 ), which accounted for 18.4% of variance in this measure. Higher total income was the primary significant predictor of greater heroin unit purchase amounts and daily bags consumed (explaining 15.8% and 48.3% of variance in these two measures, respectively), whereas income was a secondary predictor of the 'weekly heroin investment' score (6.8%, in contrast to 18.4% explained by BDNF genotype; see lower right panel of Fig. 2 and Table 3 ).
In parallel regression analyses, BDNF genotype was not significantly related to number of weekly heroin purchases or number of daily bags consumed. Rather, the number of weekly purchases was higher for subjects with more heroin suppliers and those who were younger (explaining 10.8% and 7.1% of the incremental variance, respectively).
BDNF Val 66
Met genotype and cigarette/nicotine use
Prevalence of smoking is very high among heroindependent individuals, including this sample, providing the opportunity to examine whether BDNF genotype impacts this other stable form of (legal) drug use. The influence of BDNF genotype on cigarette purchasing and use was examined in EAs (n = 54). Eighty-seven percent reported daily cigarette use. Two stepwise multiple regressions (which included non-smoking participants) were used to predict the proportion of past-month income spent on cigarettes and the number of cigarettes smoked daily (BDNF genotype groups significantly differed in univariate analyses; see Table 2 ), controlling for age, route of heroin use, total past-month income and daily bags of heroin consumed. Relative to Val homozygotes, Met carriers reported spending a significantly higher proportion of income on cigarettes (standardized b = 0.33, t = 2.52, adjusted r 2 = 0.092) and smoking significantly more cigarettes daily (standardized b = 0.27, t = 2.01, adjusted r 2 = 0.073). No other predictors were significant.
DISCUSSION
The BDNF
66
Met allele has been repeatedly associated with neurobehavioral deficits, including hippocampal and frontal-cortical volume loss, and impaired learning/ memory. The Met allele leads to less BDNF secretion and reduced neurotrophic influence, which may decrease organismic behavioral flexibility or adaptive fitness. In this study, we theorized that the 66 Met allele may confer resistance to environmentally or pharmacologically induced changes in drug-seeking, or reduced behavioral flexibility, once addictive behavior has progressed to a chronic stage. To test this hypothesis, we assessed several related phenotypes using a validated semi-structured interview method to assess past-month drug-seeking/use.
Consistent with previous large population-based data, Met allele frequency was much greater among our European-ancestral than African-ancestral subjects (21% versus 3% Met genotype and drug-seeking/use were initially observed for heroin purchase time, purchase amount and an empirically derived 'weekly heroin investment' score (purchase time ¥ amount ¥ weekly frequency); effect sizes were moderate. In stepwise multiple regression analyses that controlled for other factors that showed zero-order correlations with the BDNF genotype (younger age, higher income, more heroin suppliers and injection route of heroin use), these bivariate relationships remained significant. A significant genotype effect was not observed for number of weekly purchases or daily bags of heroin consumed. Val
Met genotype accounted for unique variance (change in r 2 value) of 7.6%, 11.1% and 18.4% in heroin unit purchase amount, purchase time and weekly heroin investment, respectively. Thus, BDNF Val 66 Met genotype was more closely related to measures of drug-seeking than consumption. This is critical for selecting an appropriate phenotype: heroin and other illegal drug users (including many in our sample) often obtain some drug free (e.g. shared by others at no cost), or through bartering (e.g. providing sex or transportation for drugs). These behavior patterns were assessed in our interview because we noted in our validation studies the potential for dissociation between drug-seeking and drug consumption. Chen et al. (2006) A limitation of this study is that the sample size was rather small, so hypotheses related to epistatic effects could not be tested with adequate statistical power. The preliminary results of this study are thus hypothesis generating, given the large number of tests performed on key phenotypes (which exhibited multi-collinearity with one another) and control variables, and-despite surviving multivariate adjustment-need to be confirmed. Nevertheless, we believe that several of these results are likely correct due to BDNF's biological plausibility as a potential mediator or moderator of addictive behavioral processes. Specifically, there is growing evidence that BDNF is involved in behavioral sensitization following repeated exposure to abused drugs including opioids. For instance, BDNF interacts closely with the dopamine D3 autoreceptor (DRD3; Le Foll et al. 2005) , which controls phasic dopamine activity (Sokoloff et al. 2006) and is implicated in conditioned drug-seeking behavior (Everitt & Robbins 2000) . Striatal BDNF/DRD3 interactions could be one candidate mechanism by which drug-seeking is sensitized and instantiated as habitual behavior (Vanderschuren & Kalivas 2000; Gerdeman et al. 2003) . This suggests important avenues for research, including whether dopamine polymorphisms could act in epistasis with BDNF to modulate drug-seeking.
Given the potentially widespread neurotrophic influence of BDNF, an important question concerns the generality of its effects (behavioral specificity). In this study, we observed in EAs that BDNF Val 66 Met genotype also accounted for 9.2% of variance in purchasing (percent of income spent) and 7.3% of variance in use (daily number) of cigarettes. These findings in our predominantly male subject sample are consistent with a study of nicotinedependent smokers (Beuten et al. 2005 ) and a recent largescale genome-wide association study (The Tobacco and Genetics Consortium 2010) . Although an association of Val
Met with smoking severity was not found in the study of Beuten et al., a haplotype showed a significant relationship in male EA smokers, but not female EAs or AA smokers. Other evidence points to a role of BDNF, D3 and D1 receptor polymorphisms in nicotine addiction, specifically with quantity of tobacco smoked (Novak et al. 2010) . The BDNF Val
Met genotype thus seems to produce an effect on drug-seeking/use in EA populations that is broader than for one particular class of abused substances and may therefore be of general importance to addiction.
On the other hand, urinalysis and self-report data were collected at screening to ascertain recent use of drugs besides opioids. Results indicated that relative to BDNF Val homozygotes, significantly fewer Met allele carriers tested positive for cocaine. A similar non-significant trend was observed for cannabis use. This finding does not support the idea that the BDNF Met allele is related to generally greater substance use. Rather, these data are consistent with the hypothesis that the Met allele is a risk factor for promoting the engrained use of preferred drugs-in this case, heroin and cigarettes.
Given the present preliminary findings and published data, our working hypothesis is that the 66 Met allele, which leads to decreased BDNF secretion and less neuroadaptation due to lower rates of cell proliferation, impairs behavioral flexibility once drug self-administration becomes habitual. This neurotrophic environment may promote a range of neurobehavioral deficits. With specific regard to addiction, reduced BDNF function and its sequelae may strengthen reinforcing efficacy of preferred drugs relative to non-drug alternatives or despite pharmacotherapy. In short, selected forms of drug-seeking behavior may become entrenched and more resistant to change in BDNF Met carriers. We found reliable
Met genotype differences across opioid-seeking phenotypes (i.e. increased purchase time and increased purchase amount) and across drug classes (greater opioid and nicotine use). Taken together with prior findings, the robust effects of this genotype may implicate its broader importance for understanding and treating addictive behavior and underlying processes such as impairments in learning/ memory. If results of future work confirm the influence of this neurotrophic genotype,
Met allele carriers might require higher levels of intervention (e.g. cognitive behavior therapy or pharmacotherapy) to overcome their chronic drug use pattern. Although we observed behavioral effects of the Val 66 Met genotype in a restricted sample (small in size and primarily for EAs), this converging pattern of association increases confidence that the results are meaningful. Further research could be theoretically and clinically useful by determining whether this hypothesis applies to the habitual use of other substances.
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